Targeting mTOR in renal cell carcinoma

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2313-2320

  Hudes, Gary R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Akt; mTOR; PI3K; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; DEFOROLIMUS; EVEROLIMUS; INSULIN RECEPTOR; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P13; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BINDING; DRUG ERUPTION; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; HALF LIFE TIME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LABORATORY; LOW DRUG DOSE; NEGATIVE FEEDBACK; NEUTROPENIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 65949091346     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24239     Document Type: Conference Paper

References (48)

1. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29-86.
2. Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22: 2954-2963.
3. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev Cancer. 2003;3:155-168.
4. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-3171.
5. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res. 2003;9:2882-2886.
6. Skotnicki JS, Leone CL, Smith AL, et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res. 2001;7:3749S-3750S.
7. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262.
8. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. PNAS. 2001;98:10314-10319. (Pubitemid 32803017)
9. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. PNAS. 2005;102:802-807.
10. Inoki K, Guan K-L. Complexity of the TOR signaling network. Trends Cell Biol. 2006;16:206-212.
11. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101. (Pubitemid 40262113)
12. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4EBP1/eukaryotic translation factor 4E. Mol Cell Biol. 2004;24:200-216.
13. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004-7014.
14. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2005;12:122-127.
15. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003;9:4641-4652.
16. Baba M, Hirai S, Yamada-Okabe H, et al. Loss of von-Hippel-Lindau protein causes cell density dependent deregulation of cyclin D1 expression through hypoxia-inducible factor. Oncogene. 2003;22:2728-2738. (Pubitemid 36609588)
17. Zatyka M, Fernandes da Silva N, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002;62:3803-3811.
18. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168.
19. Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2007;177:346-352.
20. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257-2267.
21. Cho D, Signoretti S, Regan M, et al. Low expression of surrogates for mTOR pathway activation predicts resistance to CCI-779 in patients with advanced renal cell carcinoma. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Therapeutics, 2005; abstract C137.
22. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res. 2006;12:5755-5763. (Pubitemid 44629606)
23. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-2347.
24. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588-1595.
25. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26:361-367.
26. Atkins M. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
27. Rizzieri DA, Feldman E, DiPersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14:2756-2762.
28. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540. (Pubitemid 29368255)
29. Motzer RJ, Murphy BA, Bacik J, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296. (Pubitemid 34032623)
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-α, or both in advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
31. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832-841. (Pubitemid 46224183)
32. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958-3964. (Pubitemid 47477274)
33. Jac J, Giessinger S, Khan M, et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol. 2007;25(18S) Abstract 5107.
34. Motzer RJ, Escudier B, Oudard S, et al. RAD001 versus placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results of a randomized, double blind, multicenter phase III study. J Clin Oncol. 2008;26(18S pt 2):1009S. Abstract LBA5026.
35. Merchan, JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract]. J Clin Oncol. 2007;25(18S). Abstract 5034.
36. Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multitargeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract]. Proc Am Soc Clin Oncol. 2007; 25S:141s. Abstract 3512.
37. Roux PP, Shahbazian D, Vu H, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007;282:14056-14064. (Pubitemid 47100467)
38. Bermudez O, Marchetts S, Pages G, Gimond C. Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene. 2008;27:3685-3691.
39. Yu K, Toral-Barza L, Shi C, et al. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther. 2008;7:307-315.
40. Legrier ME, Yang CP, Yan HG, et al. Targeting protein translation in human nonsmall cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007;67:11300-11308. (Pubitemid 350248556)
41. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634-642.
42. Verheul HMW, Salumbides B, Van Erp K, et al. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008;14:3589-3597.
43. Shah O, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6k cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004;14:1650-1656.
44. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65:7052-7058. (Pubitemid 41161231)
45. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932-1940. (Pubitemid 46474636)
46. O'Reilly KE, Rojo F, She Q, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;6:1500-1508.
47. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005;4:1533-1540. (Pubitemid 41556435)
48. Stolovich M, Tang H, Hornstein E, et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol. 2002;22:8101-8113. (Pubitemid 35304044)